We are testing a drug called ginisortamab that blocks a protein called gremlin-1. Gremlin-1 is mainly found outside cancer cells and stops the function of other proteins called bone morphogenetic proteins (BMPs). BMP proteins work by suppressing cancer cells as they occur but in cancer, this mechanism has often been switched off. Blocking gremlin-1 with ginisortamab will allow BMP protein function, and we hope this will change the way the cancer cells develop, making them more sensitive to chemotherapy. We are testing ginisortamab ...

GO TO STUDY

Research question In patients who have a high-risk primary cutaneous squamous cell carcinoma (HR-cSCC) surgically excised with clear margins,is adjuvant radiotherapy plus close clinical follow-up superior in reducing the risk of loco-regional recurrence compared with close clinical follow-up alone,and if so,is it cost-effective? Background cSCC is the second most common skin cancer in the UK,with annual incidence exceeding 52,000,increasing by 6% p.a (1,2). Treatment,usually surgery,is curative in 95% (3,4). However,5% of patients develop loco-regional recurrence (LRR) which causes 75% of cSCCspecific mortality,substantial morbidity and reduced quality of life (QoL) ...

GO TO STUDY

Myeloma is a treatable, but incurable, malignancy of plasma cells in the bone marrow (BM). It represents the final stage in a continuum of plasma cell disorders (PCDs) and is consistently preceded by a premalignant phase termed monoclonal gammopathy of undetermined significance (MGUS). MGUS therefore provides the opportunity to study how a premalignant condition progresses into cancer. MGUS-to-myeloma progression requires multiple genomic events and establishment of a permissive bone marrow microenvironment (BME). Historically, obtaining patient material to study MGUS has ...

GO TO STUDY

The proposed trial tests whether the addition of revumenib,compared to placebo,to azacitidine/venetoclax improves outcome in newly diagnosed adult patients with NPM1-mutated AML,who are not considered candidates for intensive chemotherapy by measuring overall survival. Newly diagnosed,previously untreated patients ≥18 years of age with NPM1-mutated or KMT2A-rearranged AML that are eligible for the study will be randomised in a 1:1 ratio to therapy with azacitidine/venetoclax with revumenib or placebo. Treatment will be on a continuous 28-day cycle schedule and continued until disease progression,development ...

GO TO STUDY

Perthes’ disease is a rare condition of the hip joint and one of the most disabling conditions affecting children. It has a profound impact on the life of the child, and that of their family. Perthes’ disease is caused by a problem with the blood supply to the hip, which means the ball doesn’t get enough oxygen and nutrients to grow. When this happens, the hip loses its strength and flattens. In Perthes’ disease there is a temporary loss of blood ...

GO TO STUDY

The proposed trial test whether the addition of venetoclax,compared to placebo,with azacitidine and ivosidenib improves outcomes in newly diagnosed adult patients with IDH1 mutated AML,who are not considered candidates for intensive chemotherapy by measuring event free survival.. Newly diagnosed,previously untreated patients ≥18 years of age with IDH1-mutated or IDH1 mutated MDS/AML that are eligible for the study will be randomised in a 1:1 ratio to therapy with ivosidenib /azacitidine with venetoclax or placebo. Treatment will be on a continuous 28-day cycle ...

GO TO STUDY

A break to the bone of the upper arm at the shoulder is a painful injury. It results in a sudden loss of use of the arm with recovery taking many months. Most injuries occur in people over 50 years of age after a fall, due to reduced bone strength, and are usually treated with a sling, although some fractures may need surgery. Currently, people are asked to see a physiotherapist a number of times to help with recovery after ...

GO TO STUDY

AIM To explore if it is possible to carry out a study testing a fatigue self-management programme for people who survive an intensive care unit (ICU) admission. WHAT DO WE KNOW? Patients with life-threatening illness require care in an ICU. Approximately half of those who survive (approx. 82,000 per year) report fatigue lasting for a year or more. Fatigue is described as an overwhelming physical and mental exhaustion, not relieved by rest or sleep. Fatigue has a devastating impact on ...

GO TO STUDY

This will be a prospective, observational, cohort study to evaluate if imaging abdominal organs could help improve clinical care by accurately identifying complications of type 2 diabetes (T2D). Participants with T2D and concurrent diabetic retinopathy will be recruited from Moorfields Hospital NHS Foundation Trust in London. Participants will be treated and assessed in line with normal clinical care. Type 2 diabetes often leads to more complicated diseases. People with T2D could also develop eye, liver disease, chronic kidney disease and cardiovascular ...

GO TO STUDY

1. Study Objectives The main aim of DARFI is to: - Establish a national collaborative database platform for the study of atypical and rare fractures. - Create a shared platform linking Major Trauma Centres,Trauma Units and District General Hospitals across the UK. - Enable high-quality,large-scale research on rare fracture types that would be impossible to study meaningfully at single centres. - Identify patterns,predictors of poor outcomes,and factors influencing treatment choices (e.g. when early surgery is required or when conservative treatment may be equally effective). 2. ...

GO TO STUDY